News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
24,185 Results
Type
Article (424)
Company Profile (2)
Press Release (23759)
Section
Business (11579)
Career Advice (9)
Deals (1831)
Drug Development (2301)
Employer Resources (2)
FDA (327)
Job Trends (438)
News (15253)
Policy (774)
Tag
Academia (60)
Accelerated approval (1)
Allergies (3)
Alliances (840)
ALS (1)
Alzheimer's disease (30)
Antibody-drug conjugate (ADC) (2)
Approvals (338)
Artificial intelligence (2)
Autoimmune disease (7)
Automation (1)
Bankruptcy (5)
Best Places to Work (414)
Biosimilars (4)
Biotechnology (3)
Bladder cancer (2)
Breast cancer (30)
Cancer (129)
Cardiovascular disease (10)
Career advice (8)
CAR-T (3)
Cell therapy (8)
Cervical cancer (1)
Clinical research (2060)
Collaboration (13)
Compensation (16)
Complete response letters (2)
COVID-19 (85)
CRISPR (3)
C-suite (6)
Cystic fibrosis (2)
Data (185)
Depression (9)
Diabetes (9)
Diagnostics (220)
Digital health (3)
Drug discovery (2)
Drug pricing (1)
Earnings (10433)
Editorial (1)
Employer resources (2)
Events (3296)
Executive appointments (14)
FDA (478)
Funding (18)
Gene editing (5)
Gene therapy (3)
GLP-1 (17)
Government (138)
Guidances (100)
Healthcare (793)
HIV (2)
Huntington's disease (2)
IgA nephropathy (1)
Immunology and inflammation (1)
Immuno-oncology (2)
Indications (2)
Infectious disease (93)
Inflammatory bowel disease (1)
Influenza (1)
Intellectual property (6)
Interviews (1)
IPO (1506)
Job creations (41)
Job search strategy (8)
JPM (1)
Layoffs (7)
Legal (116)
Liver cancer (4)
Lung cancer (11)
Lymphoma (4)
Management (2)
Manufacturing (4)
MASH (4)
Medical device (790)
Medtech (795)
Mergers & acquisitions (346)
Metabolic disorders (24)
Multiple sclerosis (4)
Neurodegenerative disease (6)
Neuropsychiatric disorders (3)
Neuroscience (57)
NextGen: Class of 2026 (148)
Non-profit (123)
Now hiring (2)
Obesity (12)
Ovarian cancer (23)
Pain (1)
Pancreatic cancer (3)
Parkinson's disease (3)
Patents (12)
Patient recruitment (6)
Peanut (2)
People (1114)
Pharmaceutical (1)
Phase 1 (558)
Phase 2 (929)
Phase 3 (776)
Pipeline (403)
Postmarket research (46)
Preclinical (192)
Press Release (1)
Prostate cancer (3)
Radiopharmaceuticals (20)
Rare diseases (15)
Real estate (69)
Regulatory (615)
Reports (1)
Research institute (47)
Resumes & cover letters (1)
RSV (4)
Schizophrenia (1)
Series A (2)
Series B (2)
Sickle cell disease (1)
Special edition (1)
Spinal muscular atrophy (4)
Startups (32)
Tariffs (1)
Vaccines (17)
Venture capital (1)
Weight loss (4)
Women's health (2)
Date
Last 7 days (11)
Last 30 days (46)
Last 365 days (1158)
2026 (50)
2025 (1190)
2024 (1446)
2023 (1731)
2022 (1921)
2021 (2138)
2020 (5555)
2019 (1384)
2018 (1006)
2017 (884)
2016 (456)
2015 (911)
2014 (555)
2013 (293)
2012 (419)
2011 (481)
2010 (569)
Location
Africa (10)
Alabama (8)
Arizona (9)
Asia (1517)
Australia (90)
California (365)
Canada (121)
China (24)
Colorado (18)
Connecticut (26)
Delaware (4)
Europe (2540)
Florida (40)
Georgia (12)
Idaho (1)
Illinois (38)
India (2)
Indiana (28)
Iowa (1)
Japan (4)
Kansas (2)
Kentucky (1)
Louisiana (7)
Maine (6)
Maryland (66)
Massachusetts (239)
Michigan (15)
Minnesota (64)
Missouri (2)
Montana (1)
Nebraska (2)
New Hampshire (8)
New Jersey (276)
New York (89)
North Carolina (73)
North Dakota (1)
Northern California (182)
Ohio (5)
Pennsylvania (159)
South America (19)
Southern California (153)
Tennessee (5)
Texas (44)
United States (1658)
Utah (31)
Virginia (5)
Washington State (35)
Wisconsin (2)
24,185 Results for "213".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Biobanking Market Size to Reach USD 213.53 Billion By 2034
September 10, 2025
·
1 min read
Funding
Odyssey Rebounds Off Failed IPO With $213M Series D
The autoimmune and inflammatory disease–focused company canceled plans to go public earlier this year as the IPO window slammed shut.
September 10, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Odyssey Therapeutics Announces Oversubscribed $213 Million Series D Financing to Advance Clinical Pipeline for Autoimmune Diseases
September 11, 2025
·
5 min read
Clinical Laboratory Services Market Size To Hold USD 213.8 Bn By 2030
The global clinical laboratory services market size was exhibited at USD 213.8 billion in 2022 and it is expected to hold around USD 293.6 billion by 2030, growing at a CAGR of 4.04% from 2022 to 2030.
December 19, 2022
·
8 min read
Press Releases
Anti-Hypertension Market Estimated to Reach a CAGR of 2.13% during 2024-2034, Impelled by Increasing Use of Digital Health Platforms
July 25, 2024
·
10 min read
Tome Biosciences Launches with $213M in Funding, Targets ‘New Era’ of Genomic Medicines
Backed by ARCH Venture Partners and Fujifilm, as well as technology licensed from MIT, Tome is looking to create curative cell and integrative gene therapies.
December 12, 2023
·
2 min read
·
Tyler Patchen
Lexaria’s Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results
Lexaria Bioscience Corp. announces that all data analyses from its simulated pulmonary hypertension clinical study HYPER-H21-3 have been successfully completed with positive safety and efficacy findings.
April 14, 2022
·
8 min read
Lexaria’s Clinical Hypertension Study HYPER-H21-3 Nears Completion
Lexaria Bioscience Corp. announces that its human clinical study HYPER-H21-3 is expected to complete all dosing and sample collection this week.
December 14, 2021
·
5 min read
Layoffs
Tome to Lay Off Almost All of Staff After Scaling Back Operations
Tome Biosciences, a gene editing startup that launched in late 2023 with $213 million in funding, will eliminate 131 positions in November, according to a Worker Adjustment and Retraining Act notice.
August 26, 2024
·
2 min read
·
Tristan Manalac
Drug Development
Selva Announces Preclinical Data Confirming SLV213 Potently Inhibits Infection By the SARS-CoV-2 Omicron Variant
Selva Therapeutics, Inc. (“Selva”) today announced new preclinical data demonstrating dosing of SLV213 at picomolar concentrations delivered near complete inhibition of infection by the Omicron variant of SARS-CoV-2 in a human lung epithelial cell line (A549_ACE2).
April 20, 2022
·
3 min read
1 of 2,419
Next
